TEST:

SureSeq™ Myeloid MRD Panel

Target-capture NGS provides the opportunity to evaluate many genes in a single assay. Suitability for MRD requires highly uniform and sensitive target enrichment. Our study demonstrated reliable and accurate detection of variants down to 0.05% VAF, providing researchers with the capability to use capture-based NGS for myeloid MRD monitoring.

This initial evaluation of the SureSeq Myeloid MRD Panel for MRD detection in AML patients undergoingallogeneic HSCT demonstrates the assay has high analytical sensitivity, including detection of FLT3-ITDmutations which are emerging as a clinically relevant MRD marker, and is broadly applicable to a diversepopulation of AML patients undergoing allogeneic HSCT. Prospective analyses of the clinical relevance of NGS-based MRD measurements are ongoing.

"OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."

"OGT, A Sysmex Group Company, will showcase its soon to be launched SureSeq™ Myeloid MRD Panel at booth #1423 at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, 14-18th November in Salt Lake City. The Next-generation sequencing (NGS) panel represents a substantial improvement on conventional flow cytometry and qPCR methods of detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) samples—providing outstanding sensitivity and coverage uniformity in one rapid and cost-effective assay."